

**ВЗАИМОСВЯЗЬ МЕЖДУ RAS И COVID-19, КРАТКИЙ ОБЗОР  
ПОСЛЕДНИХ ДОКАЗАТЕЛЬСТВ**

Витиэлло А. ,

Фэррара Ф.

Усл Умбрия 1, Перуджа, Италия

**THE CORRELATION BETWEEN RAS AND COVID-19, SHORT REVIEW  
OF THE LATEST EVIDENCE**

Vitiello A. ,

Ferrara F.

Usl Umbria 1, Perugia, Italy

**Резюме.** Коронавирус SARS-CoV-2 является причиной коронавирусной болезни (COVID-19), вызвавшей недавнюю глобальную пандемию, которая унесла тысячи жизней во всем мире и представляет собой проблему для здоровья, имеющую несколько прецедентов в истории человечества. Ангиотензин-конвертаза-2 (ACE-2) был идентифицирован как рецептор, который облегчает доступ к SARS-CoV-2 в клетках; данные показывают, что его концентрация варьируется на разных стадиях вирусной инфекции. Терапевтические агенты, модифицирующие ренин-ангиотензиновую систему (РАС), могут быть способны модулировать концентрацию ACE-2 и различных компонентов системы. В этой статье мы исследуем последние доказательства связи между использованием агентов, модифицирующих RAS, и заболеванием, вызванным коронавирусом 2019 (COVID-19), вызванным SARS-CoV-2. Наше исследование и критическое исследование литературы не предлагают прекращения лечения ACEIs/ARBs в клинической практике, поскольку для этого отсутствуют надежные доказательства. Тем не менее, мы рекомендуем провести дальнейшие хорошо структурированные эпидемиологические исследования, посвященные этому деликатному вопросу, которые могут дать новые важные предложения по внедрению руководящих принципов терапии.

**Ключевые слова:** COVID-19; РАС; SARS-CoV-2; Пандемия

***Abstract:***

Coronavirus SARS-CoV-2 is responsible for the Coronavirus disease (COVID-19) cause of the recent global pandemic, which is causing thousands of deaths worldwide and represents a health challenge with few precedents in human history. The angiotensin 2 conversion enzyme (ACE-2) has been identified as the receptor that facilitates access to SARS-CoV-2 in cells; evidence shows that its concentration varies during the various stages of viral infection. Therapeutic agents

modifying the renin-angiotensin system (RAS) may be able to modulate the concentration of ACE-2 and the various components of the system. In this article we examine the latest evidence on the association between the use of RAS modifying agents and coronavirus 2019 (COVID-19) disease caused by SARS-CoV-2. Our investigation and critical literature research does not suggest discontinuation of ACEIs/ARBs treatment in clinical practice as there is a lack of robust evidence. However, we recommend further well-structured epidemiological studies investigating this sensitive issue that may provide important new suggestions for implementing guidelines.

**Keywords:** COVID-19; RAS; SARS-CoV-2; Pandemic;

1           The SARS-CoV-2 (COVID-19) virus is responsible for the current global  
2 pandemic, causing thousands of deaths and responsible for a health challenge with  
3 few precedents for humanity. SARS-CoV-2 is a family of RNA viruses capable of  
4 infecting humans and causing respiratory distress syndrome with severe lung injury  
5 in some fatal cases. (1) Studies have shown that SARS-Cov-2 has about 80% of the  
6 SARS-CoV-like genome responsible for the 2003 outbreak. (2-3) Evidence shows  
7 that viral infection has several stages: in the first stages an asymptomatic or slightly  
8 symptomatic clinical course is described, the subsequent moderately severe stages  
9 characterised by a pulmonary inflammatory state, the last very severe stages  
10 characterised by a generalised inflammatory state affecting all tissues causing multi-  
11 organ dysfunction and in some cases death. (4) Biochemical interaction studies have  
12 shown that SARS-CoV-2 virus enters host cells mainly through the use of the spike  
13 protein (S) (5) (6) through the angiotensin 2 conversion enzyme receptor (ACE-2)  
14 on the cell surface (7). ACE-2 is also a conversion enzyme that is part of the renin-  
15 angiotensin system (RAS). Is there a scientific debate going on since the beginning  
16 of the pandemic, is an increase of ACE-2 responsible for a higher probability of  
17 COVID-19 infection? Lung tissues are probably an easier entry route for SARS-  
18 CoV2 because 83% of ACE-2 receptors are present in type II pneumocytes that  
19 produce surfactants that prevent  
20 to the alveoli to collapse. (8) . The RAS modulating drugs are widely used in the  
21 treatment of cardiovascular diseases, but what is the correlation between these drugs,  
22 RAS and COVID-19? Can they play a protective role by modulating the expression  
23 of RAS components? Or, on the contrary, are these drugs considered risk factors for  
24 COVID-19?

25


### 26 *Recent evidence on the Topic*

27

28           To date, it is strongly recommended not to interrupt the treatment with the  
29 usual therapy of RAS modulating drugs, because no clinical or scientific evidence

30 suggests this. (9) Agents acting on RAS can be distinguished as inhibitors of the  
31 angiotensin conversion enzyme (ACEI),  
32 Angiotensin II receptor blockers (ARB) and direct renin inhibitors (DRI) (Bavishi  
33 et al., 2020). These agents are currently indicated for the treatment of various  
34 cardiovascular diseases with excellent clinical efficacy. ACEIs are able to reduce  
35 blood pressure by acting with ACE inhibition which converts Ang I to Ang II. ARBs  
36 are Ang II antagonists on the type 1 receptor (AT-1r), finally, DRIs block plasma  
37 renin activity and inhibit the conversion of angiotensinogen to Ang I. The three  
38 different classes described above have different effects on the regulation and  
39 enzymatic expression of RAS. (10) A retrospective epidemiological cohort study  
40 using database data showed that the use of ACEI or ARB was not significantly  
41 associated with mortality and diagnosis of COVID-19, respectively. (11) Another  
42 study using electronic health records from the University of New York (NYU)  
43 Langone Health showed no significant correlation and association between the use  
44 of ACEI/ARB and the development of COVID-19 and COVID-19 severe,  
45 respectively. (12) In addition, another retrospective and multicentre study  
46 conducted on a large scale in adult hypertensive patients with COVID-19 in Hubei,  
47 China 9 , showed that the use of ACEI or ARB was significantly associated with a  
48 lower probability of mortality due to different causes than non-users of ACEI/ARB,  
49 probably for a greater and more effective management of underlying cardiovascular  
50 disease in the patients considered. Finally, some studies have not been considered  
51 because they show inconsistent data. (13) In addition, in several studies,  
52 investigations in patients receiving ACEi or ARB treatment did not have higher  
53 plasma concentrations and significant changes in ACE-2, in contrast to in vitro data.  
54 (14) In conclusion, based on currently available data and taking into account  
55 evidence of reduced mortality in cardiovascular disease, ACE-I and ARB therapy  
56 should be maintained or initiated in patients with cardiovascular disease according  
57 to current guidelines of the major scientific societies.

FIGURES



*SARS-CoV-2 penetrates cells by binding the peak viral protein (S) to ACE-2. ACE-2 converts Ang II to Ang 1-7. Ang 1-7 has opposite biological actions to Ang II, antifibrotic, antioxidant and antihypertrophic effects through the stimulation of MasR.*

*SARS-CoV-2 проникает в клетки, присоединяясь своим шиповатым вирусным белком (S) с ACE-2. ACE-2 конвертирует Ang II в Ang 1-7. Ang 1-7 обладает биологическим действием, противоположным Ang II, антифибротическим, антиоксидантным и антигипертрофическим эффектами за счет стимуляции MasR.*

**TITLE PAGE**

**The correlation between RAS and COVID-19, short review of the latest evidence**

Antonio Vitiello<sup>1</sup> Francesco Ferrara<sup>1</sup>

1:Usl Umbria 1, Perugia, Italy

**Взаимосвязь между RAS и COVID-19, краткий обзор последних доказательств**

Витиэлло А. ,  
Фэррара Ф.

Усл Умбрия 1, Перуджа, Италия

*\*author correspondence: [francesco.ferrara@uslumbria1.it](mailto:francesco.ferrara@uslumbria1.it)*

**Conflicts of interest**

None of the Authors have conflicts of interest to disclose.

**Founds**

None

**Copyright**

The authors certify that the manuscript is original, never submitted to other journal for publication before. All authors contributed equally to the manuscript and had the opportunity to revise and approve the final text.

**Disclosure statement:**

Dr. A.Vitiello has nothing to disclose

Dr. F.Ferrara has nothing to disclose

**Acknowledgement**

The authors have nothing to say about ethical standards, ethical approval and funding. This manuscript is not a clinical trial and does not violate ethical rules. No funding has been received for its preparation.



## REFERENCES

- 1) Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS ChemNeurosci. 2020 Mar 13. doi: 10.1021/acchemneuro.0c00122
- 2) Liu Z, Xiao X, Wei X, Li J, Yang , Tan H, Zhu J, Zhang Q, Wu J, Liu L.J Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV. MedVirol. 2020 Feb 26. doi: 10.1002/jmv.25726. 2.
- 3) Casella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;2020 Mar 8.
- 4) Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens. 2020 Mar 4;9(3). pi: E186.
- 5) Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–48.
- 6) Walls AC ,Park YJ ,Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell.2020 Mar 6. pii: S0092-8674(20)30262-2

7). Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell*. 2020;181:894–904.

8) Zhang, H., Penninger, J.M., Li, Y. et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med* (2020).

9) Bavishi, C., Bangalore, S., Messerli, F.H., 2016. Renin angiotensin aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction? *Prog. Cardiovasc. Dis.* 59, 253–261.

10) Antonio Vitiello, Francesco Ferrara Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know *European Journal of Pharmacology* 15 July 2000

11) Fosbøl EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, Schou M, Phelps M, Gislason GH, Gerds TA, Torp-Pedersen C, Køber L. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. *JAMA* Published online June 2020; 19: 168

12) Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. *N Engl J Med* 2020; 382: 2441–2448.

13) Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, Liu Y-M, Zhao Y-C, Huang X, Lin L, Xia M, Chen M-M, Cheng X, Zhang X, Guo D, Peng Y, Ji X-Y, Chen J, She Z-G, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang X-J, Wang X, Touyz RM, Xia J, Zhang B-H, Huang X, Yuan X, Rohit L, Liu PP, Li H. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality

among patients with hypertension hospitalized with COVID-19. *Circ Res* 2020; 126: 1671-1681

14) Sama IE, Ravera A, Santema BT, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. *Eur Heart J*. 2020;41(19):1810-1817. doi:10.1093/eurheartj/ehaa373